Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | BLM | P54132 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.52 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4717098 | 0.93 | BLM (0.68) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL35883 | 0.89 | — | — | |
| Phosphoric Acid SCHEMBL7888623 | 0.87 | LMNA (0.94) | LMNABLMCYP3A4NFKB1PMP22 | |
| Oxalic Acid SCHEMBL4100193 | 0.84 | ALDH1A1 (0.78) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL745120 | 0.81 | — | — | |
| SCHEMBL8630078 | 0.81 | LMNA (0.83) | LMNABLMCYP3A4NFKB1PMP22 | |
| Putrescine SCHEMBL16241736 | 0.81 | LMNA (0.83) | LMNABLMCYP3A4NFKB1PMP22 | |
| Alcohol SCHEMBL28954130 | 0.80 | LMNA (0.80) | LMNABLMCYP3A4NFKB1PMP22 | |
| Phosphonic Acid SCHEMBL11372166 | 0.80 | LMNA (0.80) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL4517389 | 0.79 | LMNA (0.79) | LMNABLMCYP3A4NFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1910356-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019101-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214503-A1 | Hiv Integrase Inhibitors | SAMHD1, ACIN1, API5 | LMNA 3741/4885BLM 3179/4885CYP3A4 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.